Investigational drug · Phase 3
Adabelimumab
Also called: SHR-A2102, SHR2554, SHR-1701, Chidamide analog
Not approved by FDA. In 20 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
20
20 still active
All registered trials
1
Any phase or sponsor naming "Adabelimumab"
First trial start
2021
Dec 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Adabelimumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Prostate Cancer
- Advanced Urothelial Carcinoma
- Recurrent Cervical Cancer
- Metastatic Cervical Cancer
- Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
- HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Follicular Lymphoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Cervical cancer · Oncology · Hematology and blood cancers · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Adabelimumab" as an intervention, largest first.
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07175220 · 200 participants (planned) · Start Oct 9, 2025 · Primary completion Oct 2028
Drug: SHR2554; SHR-A2102; SHR2554; Adabelimumab and 1 more · For: Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.
Zhong R, Hong H, Yan M, et al. · Lancet Oncol 2026
- A bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β1 (SHR1701) enhanced preclinical antitumor activity in oral squamous cell carcinoma.
Li W, Fang S, Cao Y, et al. · Oral Oncol 2026
- Breaking immune exclusion in cold tumors via TGF-β pathway inhibition.
Zhang M, Sun Y, Chen L, et al. · Expert Opin Biol Ther 2026
- From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting.
Yi M, Li T, Wu K, et al. · J Immunother Cancer 2026
- Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Tang W, Lv Y, Xie H, et al. · Cancer Lett 2026
- A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.
Xue R, Wei M, Yuan J, et al. · Signal Transduct Target Ther 2025
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- AumolertinibSHR-A2009, HS-10296Phase 37 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.